MDT · News · 20261021N
Regulatory Approval Milestones
Medtronic plc · 2026-10-21 · Importance 38 · Surprise 60 · In source text
Medtronic received European CE mark approval for its Vitalis portfolio of five next-generation pacemakers. The devices are designed for conduction system pacing therapy and include remote-monitoring features. The approval expands Medtronic’s authorized cardiac-device offering in European markets, although the reporting provides no quantified revenue or cost impact.
Key facts
- Medtronic secured European CE mark approval for its Vitalis portfolio of five next generation pacemakers tailored to conduction system pacing therapy. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | probable | — | Medtronic secured European CE mark approval for its Vitalis portfolio of five next generation pacemakers tailored to conduction system… |